# Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

> **NCT04473716** · PHASE1 · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Oral Cancer
- Induction Chemotherapy
- Programmed Cell Death 1 Inhibitor
- Inductive Therapy

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Paclitaxcel
- **DRUG:** Cisplatin
- **PROCEDURE:** Radical surgery
- **RADIATION:** Post-operative radiotherapy/chemoradiotherapy

## Key facts

- **NCT ID:** NCT04473716
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2021-04-12
- **Final completion:** 2023-09-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04473716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04473716, "Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04473716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*